RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase-III study Meeting Abstract


Authors: Motzer, R. J.; Escudier, B.; Oudard, S.; Porta, C.; Hutson, T. E.; Bracarda, S.; Hollaender, N.; Urbanowitz, G.; Kay, A.; Ravaud, A.
Abstract Title: RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase-III study
Meeting Title: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 26
Issue: 15 Suppl.
Meeting Dates: 2008 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2008-05-20
Start Page: 256s
Language: English
ACCESSION: WOS:000208457401925
DOI: 10.1200/jco.2008.26.15_suppl.lba5026
PROVIDER: wos
Notes: Meeting Abstract: LBA5026 -- Full text available in Journal of Clinical Oncology 26(18 Suppl.): 1009s and online -- Source: Wos
Altmetric Score
MSK Authors
  1. Robert Motzer
    707 Motzer